Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen - LARVOL DELTA

Evaluating thymic stromal lymphopoietin (TSLP) as a biomarker in acute graft versus host disease (ASH 2025) - "The role of TSLP in the pathogenesis of GVHDand the efficacy of targeting TSLP in the treatment of GVHD are not known and warrant investigation.Tezepelumab, a monoclonal antibody that binds to TSLP, indirectly downregulates JAK-STAT-mTORsignaling downstream of the TSLP receptor, has shown a well-tolerated safety profile in clinical trials andis approved for use in severe asthma. Therefore, TSLP has the potential to be a targetable biomarker inaGVHD. Molecular characterization of the newly discovered isoforms, including phosphorylation status, isbeing studied by our group.PS and IEL contributed equally to this study."

Biomarker • Stroma • Acute Graft versus Host Disease • Asthma • Gastrointestinal Disorder • Graft versus Host Disease • Immunology • Inflammation • Respiratory Diseases • CD4 • CRLF2 • IL13 • IL4 • IL5 • IL7 • REG3A • TNFA • TSLP

Biological therapy in severe occupational asthma (BTS WM 2025) - "There is limited data on use of biologics in OA, with only one published study on omalizumab...Most patients were prescribed Tezepelumab (n=6) and over 60% had trialled at least 1 biologic...Over half were unemployed suggesting poor employment outcomes for severe OA. Further research to explore prevalence of OA among severe asthma and better characterise treatment responses where exposures may continue is important for this underrepresented population."

Asthma • Immunology • Respiratory Diseases

Uniform clinical benefit of biologic therapy across a regional severe asthma network (BTS WM 2025) - "Patients were prescribed: benralizumab n=442, dupilumab n=69, mepolizumab n=146, omalizumab n=51, tezepelumab n=69, not recorded n=29. Download figure Open in new tab Download powerpoint Abstract P196 Figure 1 Conclusions Following the initiation of asthma biologic therapies, acute hospital attendances, health-related quality of life and both acute and chronic corticosteroid usage improved. Whilst acknowledging both the limitations of this unblinded, non-controlled observational study but also the strengths of real-world clinical service data, the positive impact of asthma biologics on multiple patient-centred clinical endpoints is profound."

Clinical • Asthma • Immunology • Respiratory Diseases

Key role of thymic stromal lymphopoietin as a molecular target for biologic treatment of severe asthma. (PubMed, Front Allergy) - "These positive outcomes have been verified by randomized clinical trials, as well as by preliminary real-life studies. The aim of this narrative review is to provide an overview of the pathogenic involvement of TSLP in asthma, followed by an updated discussion focused on the therapeutic effects induced by tezepelumab in severe asthmatic patients."

Clinical • Journal • Review • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • CRLF2 • TSLP

Modifying the course of asthma: mechanisms and strategies for clinical remission. (PubMed, Curr Opin Allergy Clin Immunol) - "Clinical remission in asthma is now a feasible target. Achieving this goal requires a multidimensional approach that integrates biologics, early treatment, comorbidity management, and lifestyle interventions. Standardized definitions and biomarkers are essential to guide therapeutic decisions and predict long-term outcomes."

IO biomarker • Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • Tobacco Cessation

The current evidence regarding the efficacy of tezepelumab administered for asthma on T2-related comorbidities. (PubMed, Expert Rev Respir Med) - "Electronic search queries were applied to PubMed and Medline databases by using the following terms: 'tezepelumab,' 'severe asthma,' 'allergic rhinitis' (AR), 'chronic rhinosinusitis,' 'nasal polyps' (CRSwNP), 'aspirin exacerbated disease (AERD),' 'atopic dermatitis' (AD), 'eczema,' 'chronique spontaneous urticaria' (CSU),'food allergy' (FA), 'eosinophilic esophagitis' (EE). No consistent data exists regarding FA and EE. Future studies are needed to confirm the efficacy of tezepelumab on AR, FA and EE."

Journal • Allergic Rhinitis • Allergy • Asthma • Atopic Dermatitis • Chronic Rhinosinusitis With Nasal Polyps • Dermatitis • Dermatology • Eosinophilic Esophagitis • Food Hypersensitivity • Gastrointestinal Disorder • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis • Urticaria

Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea (clinicaltrials.gov) - P=N/A | N=150 | Not yet recruiting | Sponsor: AstraZeneca | Initiation date: Nov 2025 ➔ Nov 2026

Trial initiation date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

How to choose a biologic agent considering comorbidities of bronchial asthma. (PubMed, Respir Investig) - "Herein, we summarize recent evidence on the prevalence of comorbidities associated with type 2 inflammation, including chronic spontaneous urticaria, atopic dermatitis, prurigo nodularis, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, eosinophilic otitis media, aspirin-exacerbated respiratory disease, allergic rhinitis, allergic bronchopulmonary mycosis, obesity, and chronic obstructive pulmonary disease, and review the efficacy of five major biologics (omalizumab, mepolizumab, benralizumab, dupilumab, and tezepelumab) in these settings. In conclusion, the assessment of comorbidities in addition to biomarkers is essential for tailoring biologic therapies for severe asthma. Integrating comorbidity profiles into treatment strategies allows for a more precise and effective use of biologics, ultimately improving outcomes in complicated asthma cases."

Journal • Review • Allergic Rhinitis • Asthma • Atopic Dermatitis • Chronic Obstructive Pulmonary Disease • Chronic Rhinosinusitis With Nasal Polyps • Chronic Spontaneous Urticaria • Dermatitis • Dermatology • Eosinophilic Granulomatosis With Polyangiitis • Genetic Disorders • Immunology • Inflammation • Langerhans Cell Histiocytosis • Nasal Polyps • Obesity • Otorhinolaryngology • Prurigo Nodularis • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Sinusitis • Urticaria • Vasculitis • IL5 • TSLP

Current practices, perceptions and future challenges in the management of moderate to severe COPD: a cross-sectional survey of respiratory consultants in the Republic of Ireland. (PubMed, BMJ Open Respir Res) - "Our study highlights insufficient access to PR and COPD MDTs, variable attitudes towards LTNIV and LVR, and uncertainty around the role of biologics in COPD care. While the modest response rate may limit generalisability, our findings underscore the need to address infrastructural and systemic barriers to optimise care pathways for moderate to severe COPD in the ROI."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Emerging IgE and non-IgE targeted therapies for chronic urticaria. (PubMed, Ann Allergy Asthma Immunol) - "Dupilumab received FDA approval for antihistamine refractory chronic spontaneous urticaria (CSU) supporting the targeting of type-2 cytokines, IL-4 and IL-13, in this disease. Bruton's tyrosine kinase (BTK) inhibitors show promise, with remibrutinib receiving FDA approval and demonstrating significant reductions in UAS7 in Phase 3 trials. c-Kit (c-Kit or KIT) inhibition with barzolvolimab shows robust efficacy with sustained effects post-treatment...Although some programs have been discontinued due to safety concerns or lack of efficacy such as fenebrutinib (BTK inhibitor), THB001 (c-Kit inhibitor), EP262 (MRGPRX2 antagonist), tezepelumab (anti- TSLP), as well as lirentelimab and AK006 (Siglec-targeting agents), these studies have informed many of the other positive studies. In summary, over the last year, we have seen the CU pipeline mature with multiple Phase 3 programs and new approvals representing diverse mechanisms of action. Nevertheless, significant..."

Journal • Review • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria • IL13 • IL4 • TSLP

Comparative Effectiveness of Tezepelumab and Dupilumab in Asthma: A Multinational Retrospective Cohort Study. (PubMed, J Allergy Clin Immunol Pract) - "No significant difference in exacerbation risk was found between dupilumab and tezepelumab. Since residual confounding may exist, further investigation is warranted to guide the selection of biological therapies in clinical practice."

HEOR • Journal • Retrospective data • Asthma • Genetic Disorders • Immunology • Obesity • Pulmonary Disease • Respiratory Diseases

Efficacy of tezepelumab in reducing oral corticosteroid use in severe asthma. (PubMed, Lancet Respir Med) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trial. (PubMed, Lancet Respir Med) - P3 | "After 52 weeks of open-label tezepelumab treatment, nearly 90% of patients with OCS-dependent severe, uncontrolled asthma had a maintenance OCS dose of 5 mg per day or less and more than 50% completely discontinued OCS, while maintaining asthma control. These findings indicate that tezepelumab treatment can help enable patients with severe asthma to reduce their OCS use and its associated burden, with broad applicability across patient phenotypes."

Journal • P3 data • Allergy • Asthma • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

On-treatment clinical remission with tezepelumab in OCS-dependent patients with severe asthma in WAYFINDER (BTS WM 2025) - "Conclusion Over 20% of individuals with SA continue to exacerbate frequently despite tezepelumab. Reduced efficacy in patients with lower baseline FeNO, child-onset asthma and the absence of nasal polyposis all point to an increased likelihood of non-T2 related exacerbation events in these patients."

Clinical • Asthma • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases

Tezepelumab reduces OCS use and improves sino-nasal symptoms in OCS-dependent patients with severe asthma and comorbid chronic rhinosinusitis (overall and with nasal polyps): results from the phase 3b WAYFINDER study (BTS WM 2025) - "*Data missing for 3 patients Conclusions Tezepelumab led to significant improvements in OCS use, asthma control, and T2 markers in a real-world setting. Two-thirds of patients had a positive response, with a subset (22%) achieving clinical remission, demonstrating clinical benefits of Tezepelumab in managing severe asthma in routine care."

Clinical • P3 data • Asthma • Immunology • Musculoskeletal Pain • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Tezepelumab reduces inflammatory biomarkers in adults with severe chronic rhinosinusitis with nasal polyps with and without comorbid asthma: results from the phase 3 WAYPOINT study (BTS WM 2025) - P3 | "Tezepelumab significantly reduced levels of all biomarkers, except those associated with neutrophils, compared with placebo in the overall population and in patients with comorbid asthma ( figure 1 ). Download figure Open in new tab Download powerpoint Abstract S161 Figure 1 Changes from baseline to week 52 in nasal polyp eosinophil-derived neurotoxin (A) and neutrophil elastase (B) levels overall and among patients with comorbid asthma Conclusion Tezepelumab reduced levels of type 2 inflammatory biomarkers compared with placebo in adults with severe CRSwNP, both in the overall study population and in patients with comorbid asthma."

Biomarker • Clinical • P3 data • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis • ELANE • IL13 • IL5 • MPO • TSLP

Path to consensus: patient and physicians perspectives on reducing background medication in patients with severe asthma controlled on biologic therapy in the UK (BTS WM 2025) - "Introduction and Objectives Tezepelumab is indicated in severe uncontrolled asthma (SuA) patients aged ≥12 years inadequately controlled despite high-dose inhaled corticosteroids plus maintenance treatment...The study is ongoing, final analyses will include approximately 350 patients. Sponsored and funded by AstraZeneca"

Clinical • Asthma • Immunology • Respiratory Diseases

Managing ABPA with tezepelumab: a single-centre experience (BTS WM 2025) - "In comparison with a prior biologic study 1 conducted at our centre, the reduction in exacerbation rate with Tezepelumab was greater than that observed with anti-IgE therapy (2.0 to 1.0) and comparable to the reductions seen with Mepolizumab (4.0 to 1.0, p <0.0001) and Benralizumab (5.0 to 2.0, p =0.0156). 'Real-World Effectiveness of Biologic Therapy in Allergic Bronchopulmonary Aspergillosis.' The Journal of Allergy and Clinical Immunology: In Practice 13. 2025; 5 :1094–1102."

Clinical • Allergic Bronchopulmonary Aspergillosis • Asthma • Cystic Fibrosis • Genetic Disorders • Immunology • Inflammation • Respiratory Diseases • TSLP

The impact of biologics in severe asthma: real-world registry data from the East of England (BTS WM 2025) - "Download figure Open in new tab Download powerpoint Abstract P204 Figure 1 Scatter plot of the change in FEF25–75% against change in FeNO showing linear regression line and 95%CI Conclusions The response to tezepleumab was relatively greater in small than large airways. Moreover, suppression of FeNO but not eosinophils with tezepelumab was associated with improvements in FEF25–75, in keeping with expression of IL13 but not IL5 in small airways smooth muscle."

Clinical • Real-world • Real-world evidence • Asthma • Immunology • Respiratory Diseases • IL13 • IL4 • IL5 • TSLP

Real world outcomes of Tezepelumab in obese and non-obese severe asthmatics (BTS WM 2025) - P3 | "Methods WAYFINDER was an open-label, single-arm, OCS-sparing study in adults with severe asthma receiving mOCS (prednisone/prednisolone 5–40 mg/day or equivalent) for ≥ 3 months before study entry. Download figure Open in new tab Download powerpoint Abstract P198 Figure 1 Conclusions Tezepelumab enabled patients with severe asthma and CRS (with or without NP) to reduce or discontinue their mOCS use, while improving sino-nasal symptoms. These data contribute to the growing evidence of the efficacy of tezepelumab in patients with CRS, including CRSwNP."

Clinical • Real-world • Real-world evidence • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Obesity • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Phenotypic characteristics associated with frequent asthma exacerbations on tezepelumab (BTS WM 2025) - "Importantly, these outcomes were achieved consistently across the Portsmouth network of hospitals, including both specialist and district general settings. This reinforces the effectiveness and equity of biologic delivery across decentralised asthma care models, supporting their continued integration across regional and national severe asthma services."

Asthma • Immunology • Respiratory Diseases

Real World Experience; an interim analysis of effectiveness of tezepelumab in patients with severe uncontrolled asthma across the UK (BTS WM 2025) - "C) demonstrates an inverse relationship between ACT and PACT score Conclusion The model reliably synthesizes clinically relevant data into a single score that predicts need for biologic therapy, persistence of T2 inflammation, and patient reported outcomes. This tool has potential to streamline asthma diagnosis and monitoring by providing clinicians with a quantitative, longitudinal assessment of both disease presence and control."

Clinical • Real-world • Real-world evidence • Asthma • Immunology • Inflammation • Respiratory Diseases

Suppression of FeNO but not eosinophils with tezepelumab is associated with improvements in small airways in uncontrolled severe asthma (BTS WM 2025) - P4 | "Introduction and Objectives Spirometry-derived ratios can be used to distinguish restrictive and obstructive lung disease and guide treatment decisions in patients with asthma. View this table: View inline View popup Download powerpoint Abstract P197 Table 1 Change from baseline in spirometry-derived ratios over time in patients with type 2, moderate-to-severe asthma from VESTIGE Conclusions In patients with type 2, moderate-to-severe asthma, dupilumab significantly increased spirometry-derived ratios, indicating improved large and small airway function. Increases in these ratios correlated with reductions in FeNO and improvements in asthma control."

Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • IL13

Is T2 -guided treatment feasible in asthma exacerbations? (BTS WM 2025) - P3 | "The proportion of patients achieving all clinical remission criteria was 12.4% (28/226) at week 28 and 24.3% (51/210) at week 52 ( figure 1 ). Download figure Open in new tab Download powerpoint Abstract P202 Figure 1 Proportion of WAYFINDER participants who achieved on-treatment clinical remission at week 28 and week 52 Conclusions About a quarter of OCS-dependent patients with severe asthma achieved clinical remission by 52 weeks of tezepelumab treatment."

Asthma • Immunology • Respiratory Diseases

Dupilumab causes improvements in spirometry ratios in patients with moderate-to-severe asthma, which correlate with changes in fractional exhaled nitric oxide and asthma control (BTS WM 2025) - "Use of Tezepelumab does not require raised eosinophils or FeNO so it may be able to reach this population. However, this may be affected by the number of patients who did not complete a 12-month trial because of adverse effects or non improvement in symptoms. There is a need for other management options in obesity related severe asthma."

Clinical • Asthma • Genetic Disorders • Immunology • Musculoskeletal Diseases • Musculoskeletal Pain • Obesity • Orthopedics • Respiratory Diseases